• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Sat, 12.07.25

ORIGINAL ARTICLES

IMAJ | volume 27

Journal 6, June 2025
pages: 358-362

Topical Tranexamic Acid-mediated with Non-insulated Microneedling Radiofrequency for the Treatment of Melasma

1 Clalit Healthcare Services, Petah Tikva, Israel 2 Department of Dermatology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel 3 Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel 4 Adelson School of Medicine, Ariel University, Ariel, Israel 5 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel 6 Assuta Medical Center, Tel Aviv, Israel

Summary

Background:

Radiofrequency-skin interaction is considered self-limited for treating acquired pigmentation such as melasma. Alternatively, skin perforation with microneedling radiofrequency (MNRF) may increase skin bioavailability for depigmenting-mediated ingredients or drugs for the treatment of melasma.

Objectives:

To examine the clinical feasibility of topical tranexamic acid (TA) mediated with MNRF-assisted transepidermal delivery in patients with mixed melasma.

Methods:

The study protocol included 14 women with centrofacial or malar pattern of distribution of melasma (skin types II-VI; age 35–48 years). Patients underwent four treatments at 3-week intervals between treatments. Treatment protocol included non-insulated MNFR (Intensif, EndyMed Ltd, Caesarea, Israel) followed by TA (hexakapron 4%) solution application. The improvement was evaluated based on clinical photographs (Quantificare, Biot, France) and modified Melasma Area and Severity Index (mMASI) scores. Baseline Photographs were analyzed 3 months after the last treatment.

Results:

In 13 patients (93%), mMASI scores were significantly lower after 3 months (mean 3.6) than at baseline (5.22). In one patient, mMASI was higher at 3 months compared to baseline. Overall, mMASI improved by 31% (P < 0.01). Physician and patient satisfaction was high. Minimal adverse reactions were recorded.

Conclusions:

MNRF-assisted transepidermal delivery with topical TA is a safe and effective modality for the treatment of melasma.

Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel